Neutralizing monoclonal IgG antibodies against both TGF-β (fresolimumab) and TGFBRII (LY3022859) have demonstrated a significant decrease in tumor growth and metastasis in animal models and phase-II clinical trials [87,88]. This evidence concerns the gene TGFB1 and neoplasm.